Idorsia Ltd
🇩🇪XFRA.19TGermanyNot reported
Price€4.70-0.12 (-2.49%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 5
- Medium: 2
- Low: 0
Asset turnover: a sudden spike above its trailing quarter average
Capital expenditure to revenue: a sudden spike above its trailing quarter average
Effective tax rate: a sudden drop below its trailing quarter average
Fixed asset turnover: a sudden spike above its trailing quarter average
Working capital turnover: a sudden drop below its trailing quarter average
Free with a Finzer account.
Profile
- Germany
Identity
- Exchange
- Frankfurt Stock Exchange . XFRA
- Type
- Stock
- ISIN
- CH0363463438
- CUSIP
- Not reported
Company
- Employees
- Not reported
- Headquarters
- Germany
- Website
- Not reported
Market
- Shares outstanding
- 269.1M
- Market cap
- €960.22M
Key dates
- Next earnings
- Oct 29, 2026
Highlights
- Market cap
- €960.22M
- EPS LTM
- -CHF 0.65
- P/E LTM
- Not reported
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CHF 217.23M+69.92%up year on year
- Net income
- -CHF 133.26M-564.99%down year on year
- Gross margin
- 49.28%-42.47%down year on year
- Free cash flow
- -CHF 261.77M+37.9%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Idorsia Ltd is listed on Frankfurt Stock Exchange (Germany) under the ticker 19T. Its market capitalisation is €960.22M, from 269.1M shares outstanding, as of . Across the 252 trading sessions to the shares traded between €3.18 and €8.09, and the last close of €4.70 sits 31% of the way up that range. This is the Frankfurt Stock Exchange listing of Idorsia Ltd; its primary listing is IDIA on SIX Swiss Exchange.
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.